12,372 trials
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Papillomavirus Infections
Primary: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine — 100; 100; 100; 100 Percentage of Participants
Cervical Cancers · Vulvar Cancers · Vaginal Cancers
Primary: Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study — 91.1; 43.9 Percentage of Participants
Papillomavirus Infections
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 1637.9; 1725.0; 1170.3; 1212.6 milli Merck…
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) — 0.5; 15.8 Cases per 10,000 person-years follow-up — p=<0.0001
Fibromyalgia
Primary: Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM) — -1.90; -1.58 units on a scale…
Japanese Encephalitis
Primary: SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose — 100; 100…
Pain
Primary: Brief Pain Inventory (Pain) — 3.57; 4.59 units on a scale
Encephalitis
Primary: Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination — 33.3; 20.7; 3.4 percentage of participants
Multiple Sclerosis
Primary: Core Treatment Period: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) — 14.3; 8.7; 9.0; 26.0 percent probability — p=0.0087
Psoriasis
Primary: The Percentage of Participants Achieving a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12 — 5.4; 67.6; 69.4 Percentage of…
Spondylitis, Ankylosing
Primary: Percentage of Participants Achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 Response at Week 16 — 71.1; 40.0 Percentage of Participants — p=<0.0001
Vitamin B6 Deficiency
Primary: Total Remethylation of Homocysteine — 6.07; 5.63 micromol/(kg x hr) — p=0.20
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 85.5; 83.6; 70.8; 80.3 percentage of participants